Abstract:Kidney cancer accounts for about 3% of all adult cancers.1 The incidence of renal cell carcinoma (RCC) in Canada and the United States is increasing at a rate of 2% to 2.5% per year.1,2 The incidence of RCC in the United States increased from 7.1 per 100 000 in the early 1980s to 10.9 in 2002. Most of this rise is at the expense of incidentally detected small renal masses (SRMs) likely due to the more frequent use of abdominal imaging. In 1970, 10% of RCCs were detected incidentally, compared with more than 60% in 1998. These incidentally detected SRMs portend a better prognosis than symptomatic ones. Patard and colleagues described that the 73 months disease-free survival for incidentally detected tumours was 93% compared with 59% for those that presented with symptoms. These incidentally detected SRMs are more likely to be of benign histology, smaller, of lower stage and lower grade.3 Cooperberg and colleagues demonstrated that the mean tumour size at diagnosis decreased from 4.1 to 3.6 cm between 1993 and 2004.4 The resected tumour size from surgical series dropped from an average largest diameter of 7.8 to 5.3 cm between 1989 and 1998.5 There has also been an increase in the proportion of renal masses £3 cm and £2 cm between 1993 and 2004 (32.5 vs. 43.4% and 24.1 vs. 29.4%, respectively). In addition, it has been described that 85% of tumours £4 cm in size were localized to the kidney (stage T1a) as opposed to 32% of those between 4 and 7 cm. Pearson and colleagues reported that only 7.2% of tumours £4 cm are stage pT3a.6 From a sample size of 18 818 patients, Rothman and colleagues reported that 86% of patient with tumours smaller than 4cm in diameter have a low Fuhrman grade.7 Patients in the seventh to ninth decades of life have experienced the largest increase in incidence with a tenfold rise between 1935-39 and 1985-89.2 This particular age group has the largest amount of comorbidities. It has been demonstrated that the 5-year overall mortality for no cancer causes and other cancers is much higher than that of kidney cancer in patients older than 65 years of age.8 While disease characteristics have changed over the last 30 years, aggressive treatment remains the standard of care for incidentally detected SRMs. Between 1983 and 2002, the incidence of renal surgery in the United States increased from 0.9 to 3.6 per 100 000, mostly at the expense of SRMs. This increase in surgical treatment does not appear to translate into better outcomes. The mortality rate for all renal tumours in the United States has increased.2,9 Furthermore, Russo and colleagues demonstrated that progression-free survival and overall survival rates have not changed between 1989 and 2004 after resection of localized kidney cancer.10 These changing trends demonstrate a treatment disconnect between the stage migration of RCC and increased surgical management and the rising disease specific mortality rate of RCC. This observation questions the risk that these incidentally detected SRMs truly represents.

Trends and costs of minimally invasive surgery for kidney cancer in the US: A population-based study

National Trends and Cost of Minimally Invasive Surgery in Urology

Open versus Minimally Invasive Nephroureterectomy: Contemporary Analysis from a Wide National Population-Based Database

Trends and Outcomes from a Wide National Population-Based Database

Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs

Assessment of mechanical bowel preparation prior to nephrectomy in the minimally invasive surgery era: insights from a national database analysis in the United States

“Minimally invasive surgery for clinical T4 Non-Small cell lung cancer: National trends and outcomes”

Factors associated with surgical refusal and non-surgical candidacy in stage 1 kidney cancer: a National Cancer Database (NCDB) analysis

Health-care expenditures are less for minimally invasive than open colectomy for colon cancer: A US commercial claims database analysis

Time trends in surgical provision and cancer-specific outcomes in patients with stage T2-3 kidney cancer: a SEER-based study

The Detrimental Effect of Metabolic Syndrome on Long-term Renal Function in Patients Undergoing Elective Partial Nephrectomy for Small Renal Masses

P1126 Navigating the Future: Minimally Invasive Surgery Trends in Ulcerative Colitis

Acute Kidney Injury and Perioperative complications based on modality of nephrectomy for the treatment of kidney cancer

Trends and disparities in access to minimally invasive distal pancreatectomy (midp): an eight-year analysis from the national cancer database

Relationship of Surgical Approach With Financial Toxicity in Patients With Resected Lung Cancer

Minimally Invasive Surgery in the United States, 2022: Understanding Its Value Using New Datasets

Comparison of health-care utilization and expenditures for minimally invasive vs. open colectomy for benign disease

Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database

The changing epidemiology of kidney cancer

Open versus minimally invasive nephroureterectomy in octogenarians: An analysis of surgical approach trends, outcomes, and survival analysis with propensity matching

Results from a Multi-Institutional Collaboration